Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Genomics of Kidney Transplantation

The major aim of this research study is to investigate the relationship between genetic variation in DNA (inherited code material in the cells of the body) and factors affecting transplant outcomes, like the drugs people receive or the way their immune systems work, for example. To do this, investigators will collect blood samples from participants. Genetic material will be separated from each blood sample and analyzed, looking for genetic variation.

Studieoversigt

Detaljeret beskrivelse

In the past, the major problems in kidney transplantation were surgical complications, acute rejection, and infections. Right now, researchers are focusing on improving immune suppression therapy and achieving better long-term survival of kidney transplants. One of the ways to try to understand what causes loss of function after many years is to find out if there is a genetic factor involved.

There are a number of differences in specific genes that have been identified and are thought to affect transplant outcomes. Studying these gene variations (differences between people or differences between populations) is important in determining whether these variations are related to transplant outcomes and how this information can help patients achieve better long-term transplant survival.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

1552

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alberta
      • Edmonton, Alberta, Canada, T6G 2B7
        • University of Alberta
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35294
        • University of Alabama
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55415
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, Forenede Stater, 55414
        • University of Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Mayo Clinic

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Targeted: 3000 Kidney or Kidney-pancreas transplant recipients and 1300 of the donors

Beskrivelse

Inclusion Criteria:

  • Kidney (or kidney-pancreas) transplant recipient no more than 10 days post-transplant or kidney donor no more than 30 days post-transplant or previously enrolled in Phase I of the Genomics of Kidney Transplantation Study;
  • No organs other than kidney or pancreas transplanted simultaneously with the qualifying kidney transplant; and
  • Participant or parent/guardian must be able to understand and provide written informed consent.

Inclusion for the Activity and mRNA Expression Cohort:

  • Recipient enrolled in the Main Cohort Study;
  • Informed consent for participation in the Activity and mRNA Expression Cohort;
  • Age 18 years or greater as of day of transplantation;and
  • Will receive tacrolimus, cyclosporine or mycophenolate as part of maintenance immunosuppression therapy.

Exclusion Criteria:

- Inability or unwillingness of the participant or parent/guardian to give a written informed consent or comply with the study protocol.

For the Activity and mRNA Expression Cohort:

- Inability or unwillingness of the participant or parent/guardian to give a written informed consent for participation in the Activity and mRNA Expression Cohort or comply with the study protocol.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Transplant Recipients Cohort
Main Study Cohort: Kidney (or kidney-pancreas) transplant recipients. Enrollment for this cohort is closed.
Transplant Donors Cohort
Main Study Cohort: The kidney donor for transplant recipients in this study. Enrollment for this cohort is closed.
Activity&mRNA Expression Substudy Cohort
A subset of subjects enrolled in the main study who will receive tacrolimus, cyclosporine or mycophenolate as part of maintenance immunosuppression therapy. This group has a prospective observational cohort design. Enrollment into the Activity and messenger ribonucleic acid (mRNA) Expression Cohort, occurring concurrently with enrollment of the rest of the study, will continue until either the required sample size of 600 is achieved or the protocol team terminates enrollment. Participants in the Activity and mRNA Expression Cohort have additional blood draws up to 2 weeks prior to transplant, at week 1, Month 3 and Month 6 post-transplant.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Transplant recipient genotypes: time to chronic graft disfunction
Tidsramme: Day 0 to Year 5
Day 0 to Year 5
Transplant recipient genotypes: time to a persistent 25% decrease in Estimated Glomerular Filtration Rate (eGFR)
Tidsramme: Day 0 to Year 5
eGFR: Estimated GFR test results are a measure of kidney function.
Day 0 to Year 5
Transplant recipient genotypes: time to acute rejection
Tidsramme: Day 0 to Year 5
Day 0 to Year 5
Transplant recipient genotypes: time to allograft failure
Tidsramme: Day 0 to Year 5
allograft failure is defined as graft loss or participant death.
Day 0 to Year 5
Donor Genotypes: time to chronic graft dysfunction
Tidsramme: Day 0 to Year 5
The time to dysfunction of the donated organ.
Day 0 to Year 5
Donor Genotypes: time to a persistent 25% decrease in eGFR
Tidsramme: Day 0 to year 5
The time to a persistent 25% decrease in eGFR in the donated organ's recipient.
Day 0 to year 5
Donor Genotypes: time to allograft failure
Tidsramme: Day 0 to Year 5
The time to the failure of the donated organ (defined as graft loss or participant death).
Day 0 to Year 5
Recipient genotypes: time to select mycophenolate-related toxicities (leukopenia, anemia)
Tidsramme: Day 0 to Year 5
Day 0 to Year 5
Recipient genotypes: time to select Calcineurin Inhibitor (CNI)-related toxicities
Tidsramme: Day 0 to Year 5
Toxicities may include: new onset diabetes or nephrotoxicity. CNI: calcineurin inhibitor
Day 0 to Year 5
Recipient genotypes: repeated measures of clinically obtained tacrolimus trough blood levels
Tidsramme: Day 0 to Year 5
Day 0 to Year 5
Recipient candidate genotypes: Calcineurin (CN) and IMPDH protein activity and expression
Tidsramme: Day 0 to Year 5
CN: Calcineurin. IMPDH: Inosine-5'-monophosphate dehydrogenase
Day 0 to Year 5

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to composite endpoint of graft loss or death or persistent 25% increase in serum creatinine
Tidsramme: Day 0 to Year 5
Day 0 to Year 5
Time to renal biopsy with presence of the following semi-quantitative pathology endpoints: patterns of Banff biopsy score, presence of circulating anti-donor anti-Human Leukocyte Antigen (HLA) antibodies, C4d positivity
Tidsramme: Day 0 to Year 5
Day 0 to Year 5
Slope of eGFR
Tidsramme: Day 0 to Year 5
Day 0 to Year 5
Delayed graft function
Tidsramme: Day 0 to Year 5
Day 0 to Year 5
Time to Epstein-Barr virus (EBV) and Cytomegalovirus (CMV) infection
Tidsramme: Day 0 to Year 5
EBV: Epstein-Barr virus. CMV: cytomegalovirus.
Day 0 to Year 5

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: A Matas, MD, University of Minnesota
  • Studiestol: A Israni, MD, MS, University of Minnesota

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. august 2012

Primær færdiggørelse (Faktiske)

1. januar 2017

Studieafslutning (Faktiske)

1. januar 2017

Datoer for studieregistrering

Først indsendt

17. oktober 2012

Først indsendt, der opfyldte QC-kriterier

25. oktober 2012

Først opslået (Skøn)

26. oktober 2012

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. juni 2017

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. juni 2017

Sidst verificeret

1. juni 2017

Mere information

Begreber relateret til denne undersøgelse

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Nyretransplantationsdonor

Abonner